These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9836381)

  • 41. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial.
    Choy EH; Panayi GS; Emery P; Madden S; Breedveld FC; Kraan MC; Kalden JR; Rascu A; Brown JC; Rapson N; Johnston JM
    Rheumatology (Oxford); 2002 Oct; 41(10):1142-8. PubMed ID: 12364634
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.
    Maini RN; Elliott M; Brennan FM; Williams RO; Feldmann M
    APMIS; 1997 Apr; 105(4):257-63. PubMed ID: 9164467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of rheumatoid arthritis with anti CD4 monoclonal antibody. Open study of 25 patients with the B-F5 clone.
    Wendling D; Racadot E; Morel-Fourrier B; Wijdenes J
    Clin Rheumatol; 1992 Dec; 11(4):542-7. PubMed ID: 1486748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-CD4 treatment of patients with rheumatoid arthritis. Is there still a place for this treatment principle in RA?
    Kalden JR
    Clin Exp Rheumatol; 1994; 12 Suppl 11():S67-9. PubMed ID: 7768057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experience with a chimeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis.
    Moreland LW; Pratt PW; Sanders ME; Koopman WJ
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S153-9. PubMed ID: 8100752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The pathogenesis of rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics.
    Panayi GS
    Agents Actions Suppl; 1995; 47():1-21. PubMed ID: 7785487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis.
    Kirkham BW; Thien F; Pelton BK; Pitzalis C; Amlot P; Denman AM; Panayi GS
    J Rheumatol; 1992 Sep; 19(9):1348-52. PubMed ID: 1279168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens.
    Choy EH; Pitzalis C; Cauli A; Bijl JA; Schantz A; Woody J; Kingsley GH; Panayi GS
    Arthritis Rheum; 1996 Jan; 39(1):52-6. PubMed ID: 8546738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biologic agents for treating rheumatoid arthritis. Concepts and progress.
    Moreland LW; Heck LW; Koopman WJ
    Arthritis Rheum; 1997 Mar; 40(3):397-409. PubMed ID: 9082924
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment with anti-CD4 monoclonal antibody and acute interstitial nephritis.
    Choy EH; Kingsley GH; Panayi GS
    Arthritis Rheum; 1993 May; 36(5):723-4. PubMed ID: 8489552
    [No Abstract]   [Full Text] [Related]  

  • 51. Human monoclonal rheumatoid factors augment arthritis in mice by the activation of T cells.
    Ezaki I; Okada M; Yoshikawa Y; Fujikawa Y; Hashimoto M; Otsuka M; Nomura T; Yamamoto K; Watanabe T; Shingu M; Nobunaga M
    Clin Exp Immunol; 1996 Jun; 104(3):474-82. PubMed ID: 9099933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluating candidate autoantigens in rheumatoid arthritis.
    Cope AP; Sønderstrup G
    Springer Semin Immunopathol; 1998; 20(1-2):23-39. PubMed ID: 9836367
    [No Abstract]   [Full Text] [Related]  

  • 53. Mycosis fungoides arthropathy.
    Berger RG; Knox SJ; Levy R; Sklar JL; Cohen P; Reichert T
    Ann Intern Med; 1991 Apr; 114(7):571-2. PubMed ID: 1825772
    [No Abstract]   [Full Text] [Related]  

  • 54. [Monoclonal antibody therapy for rheumatoid arthritis].
    Ishii T; Saeki Y
    Nihon Rinsho; 2002 Mar; 60(3):551-5. PubMed ID: 11904972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.
    Hepburn TW; Totoritis MC; Davis CB
    Rheumatology (Oxford); 2003 Jan; 42(1):54-61. PubMed ID: 12509613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis.
    Rubbert-Roth A
    Curr Opin Mol Ther; 2010 Feb; 12(1):115-23. PubMed ID: 20140823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody.
    Mauri C; Chu CQ; Woodrow D; Mori L; Londei M
    J Immunol; 1997 Nov; 159(10):5032-41. PubMed ID: 9366431
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.
    Feldmann M; Elliott MJ; Woody JN; Maini RN
    Adv Immunol; 1997; 64():283-350. PubMed ID: 9100984
    [No Abstract]   [Full Text] [Related]  

  • 59. Anti-proliferative effects induced by anti-CD4 human/murine chimeric antibody and murine anti-CD4 monoclonal antibody.
    Shen G; Zhu H; Wang X; Zhang Y; Zhu Z; Wang S
    J Tongji Med Univ; 1999; 19(1):6-9. PubMed ID: 12840865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical improvement of myasthenia gravis by treatment with a chimeric anti-CD4 monoclonal antibody.
    Ahlberg R; Yi Q; Pirskanen R; Matell G; Swerup C; Rieber P; Riethmüller G; Holm G; Lefvert AK
    Ann N Y Acad Sci; 1993 Jun; 681():552-5. PubMed ID: 8357195
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.